Jump to navigation
Enter the article’s url One of our curators will take care of it as soon as possible!
The process for correcting a published article can be needlessly burdensome. So some researchers have decided to take matters into their own hands.
Bruce Stillman, president of Cold Spring Harbor Laboratory, sat down with STAT to share his thoughts on everything from research funding to President Trump.
Science and technology are so central to the economy, defense, and other top-tier issues that President Trump should appoint a science advisor soon.
Several pricey drugs projected as best-sellers have flopped, unnerving the industry. Is the era of the biotech blockbuster over?
The Trump administration is proposing a $1.2 billion cut this year to the NIH (National Institutes of Health) budget, targeting research grants.
After flunking a calculus test, I worried I wouldn't make it in science. But I stuck with it, even as people I knew dropped out after their first failure.
In the latest ploy, a group of researchers in Poland tried to seat a fictional scholar onto the editorial boards of 360 academic publications.
For those researchers, the pressure to publish is intense, as they vie for the few jobs at the heads of academic labs. This atmosphere can lead to mistakes.
It often feels as though today’s health headlines are some scientific version of Mad Libs. And now there’s a study that provides evidence for that hunch.
A growing chorus of experts says that scientific research is using too wide a net — and therefore publishing results that turn out to be false.
Tired of alternative facts, two Seattle professors aim to strike a blow for science. Their weapon? A new course: “Calling Bullshit In the Age of Big Data.”
Dr. Patrick Soon-Shiong, a biotech billionaire, launched a 'moonshot' to vanquish cancer. But an investigation found the hype far outruns the progress.
This is one of our biggest failures as a scientific community — we haven’t done a good job of actually communicating with people about what we do.
Dr. Francis Collins, the director of NIH, "has been held over by the Trump administration," although it's unclear whether Trump may nominate a successor.
A small number of scientists band together to reference each other’s work, gaming the citation system to make their studies appear to be more important.
Fake news and "post-truth," which may have played a role in the 2016 elections, are also problems in science publishing and science journalism.
Despite the typical stigma of retracting a scientific paper, Nathan Georgette is doing just fine — serving as a model to those many decades his senior.
Open access publishing that permits commercial reuse enables the kinds of public-private partnerships that are essential to scientific innovation.
Gingrich, the former House speaker and adviser to the president-elect, said "this is going to be a very science- and technology-oriented administration."
NIH Director Dr. Francis Collins said Friday that it would be a "privilege" to remain in that post if asked to stay by President-elect Donald Trump.
Two features of peer review subvert the goals of science: reviews are kept secret and reviewers are usually anonymous, argues Jeffrey S. Flier.
Science fraud draws attention, but most scientists think it’s a far lesser threat to their field than the many times researchers cut corners.
What do Godzilla and scientific peer review have in common? Each ought to be collapsing under its own weight, yet somehow they stand.
Taking potshots at some scientific research is a pastime of American politics. But critics need to assess the merits of the research they target beforehand.
Data sharing rules are vague and institution-specific and permit researchers to erect obstacles that give them effective veto power over use of their data.
The inaugural Sentinel of Science awards aim to give peer review a bit more luster by showcasing the contributions of reviewers.
Researchers will have to publicly report the results of many more clinical trials under new government rules announced Friday.
Peer review is a thankless task, but journals have been experimenting with accolades and cash incentives for scientists who serve as peer reviewers.
An editorial argues that data sharing can cripple scientific progress and harm patients, but there are myriad flaws with that reasoning.
By one estimate, 11 biotech drugs made from the ovary cells of Chinese hamsters generated an incredible $57 billion in sales in 2013 alone.